GR Impairment in Carconogenesis: Tumor Suppressor Role
GR Impairment in Carconogenesis: Tumor Suppressor Role
批准号:
7248750
负责人:
THOMAS J SLAGA
金额:
$29.91万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-03-01 至 2010-06-30
关键词:
AdultAffectAnimalsCarcinogensCarcinomaCell LineCell physiologyDNA biosynthesisDNA chemical synthesisDevelopmentDiagnostic Neoplasm StagingEpidermisGenesGlucocorticoid ReceptorGlucocorticoidsGoalsGrowthHormonesImpairmentIn VitroInflammationInflammatory ResponseMalignant Epithelial CellMediatingMusNuclearNumbersPapillomaPhysiologicalPlayProliferatingPropertyProtein OverexpressionRepressionResistanceRoleSkinSkin CarcinogenesisSkin NeoplasmsSkin PapillomaSquamous Cell PapillomasSquamous cell carcinomaStagingTetanus Helper PeptideTranscriptional ActivationTransgenic AnimalsTransgenic MiceTumor PromotersTumor Suppressor ProteinsTumor stageUp-Regulationcarcinogenesisglucocorticoid-induced orphan receptorin vivoinhibitor/antagonistkeratin 5keratinocytepreventpromoterreceptor functionsizeskin hyperplasiatranscription factortumortumorigenesistumorigenicubiquitin ligase
中文摘要
描述(申请人提供):糖皮质激素是体内角质形成细胞中生理DNA合成的非常有效的抑制物。当这些激素与致癌物或促癌剂一起应用于皮肤时,在防止致癌物和促癌剂引起的皮肤增生、炎症和小鼠皮肤肿瘤形成方面也非常有效。然而,我们和其他人已经证明,糖皮质激素不会影响已建立的乳头状瘤、鳞状细胞癌(SCC)或体外转化的角质形成细胞的生长。此外,我们最近发现,在体外和体内,糖皮质激素确实不影响转化的角质形成细胞中的糖皮质激素反应基因。糖皮质激素对细胞功能的调控是由糖皮质激素受体(GR)介导的,GR是一种众所周知的转录因子。我们已经发现,在小鼠皮肤肿瘤中,核因子-KB转录因子被结构性激活,这似乎改变了一些GR功能。我们还发现,这种核因子-KB的激活主要是由于SCFmHOS泛素连接酶的上调。我们已经在角蛋白5(K5)启动子的控制下获得了高表达GR的皮肤靶向转基因小鼠。这些成年转基因小鼠对皮肤肿瘤促进剂的增殖和炎症反应减弱。我们的初步研究表明,K5.GR转基因动物对AS诱导的肿瘤形成具有抵抗力。在K5.GR/ras+双转基因小鼠中,表皮中GR的结构性核过度表达和激活显著地抑制了皮肤肿瘤的发展,就发生肿瘤的动物数量、每只动物的肿瘤数量和肿瘤大小而言。我们建议证明GR在小鼠皮肤癌发生中作为肿瘤抑制因子发挥作用的假设。根据这一目标,具体的目标是:1)建立皮肤GR表达缺陷的动物,并分析它们对皮肤癌发生的敏感性。2)确定GR的转录抑制活性是否足以抑制小鼠皮肤乳头状瘤和癌细胞系的致瘤特性。3)建立皮肤条件表达GR的转基因动物(TRE.GR X K5.Tet-On),确定GR的致癌阶段(S)。B)分析在肿瘤发展的不同阶段,当GR过度表达时,这些小鼠对皮肤癌的敏感性。4)分析游离糖皮质激素对皮肤炎症、角质形成细胞增殖及皮肤肿瘤发生的影响。
英文摘要
DESCRIPTION (provided by applicant): Glucocorticoid hormones are very potent inhibitors of physiological DNA synthesis in keratinocytes in vivo. These hormones are also very effective in preventing carcinogen- and tumor promoter-induced skin hyperplasia, inflamination, and mouse skin tumor formation when applied to skin together with a carcinogen or a tumor promoter. We and others have shown, however, that glucocorticoids do not affect the growth of either established papillomas, squamous ceil carcinomas (SCC), or transformed keratinocytes in vitro. In addition, we recently found that glucocorticoids do net affect glucocorticoid-responsive genes in transformed keratinocytes both; in vitro/and in vivo. The glucocorticoid control of cellular functions is mediated by the glucocorticoid receptor (GR), a well-known transcription factor. We have found that NF-KB transcription factor is constitutively activated in mouse skin tumors which appears to alter some of GR functions. We have also found that this activation of NF-KB is primarily due to up-regulation of SCFmHOS ubiquitin ligase. We have generated skin-targeted transgenic mice over-expressing GR under the control of keratin 5 (K5) promoter. These adult transgenic mice have impaired proliferative and inflammatory responses to skin tumor promoters. Our initial studies showed that K5.GR transgenic animals are resistant to /-as-induced tumorigenesis. The constitutively nuclear overexpression and activation of GR in the epidermis dramatically inhibited skin tumor development in K5.GR/ras+ double transgenic mice in terms of number of animals that develop tumors, number of tumors per animal, and tumor size. We propose to prove the hypothesis that GR functions as a tumor suppressor in mouse skin carcinogenesis. Pursuant to this goal, the specific aims are: 1) To develop animals deficient in the expression of GR in skin, and analyze their sensitivity to skin carcinogenesis. 2) To determine whether transrepression activities of GR are sufficient to suppress tumorigenic properties of mouse skin papilloma and carcinoma cell lines. 3) To determine the stage(s) of carcinogenesis where GR plays a role of tumor suppressor a) develop transgenic animals with the conditional expression of GR in skin (TRE.GR X K5.Tet-On). b) analyze the sensitivity of these mice to skin carcinogenesis, when over-expression of GR induced at different stages of tumor development. 4) To analyze the effects of dissociated glucocorticoids on skin inflammation, keratinocyte proliferation, and on skin tumor development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GR Impairment in Carconogenesis: Tumor Suppressor Role
-
批准号:7938161
-
项目类别:
-
资助金额:$16.94万
-
财政年份:2009
-
负责人:THOMAS J SLAGA
-
依托单位:
Combined Natural Inhibitors in Skin Cancer Prevention
-
批准号:6929349
-
项目类别:
-
资助金额:$36.5万
-
财政年份:2003
-
负责人:THOMAS J SLAGA
-
依托单位:
Combined Natural Inhibitors in Skin Cancer Prevention
-
批准号:6772413
-
项目类别:
-
资助金额:$40.08万
-
财政年份:2003
-
负责人:THOMAS J SLAGA
-
依托单位:
Combined Natural Inhibitors in Skin Cancer Prevention
-
批准号:6580490
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2003
-
负责人:THOMAS J SLAGA
-
依托单位:
Combined Natural Inhibitors in Skin Cancer Prevention
-
批准号:7125032
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2003
-
负责人:THOMAS J SLAGA
-
依托单位:
Combined Natural Inhibitors in Skin Cancer Prevention
-
批准号:7251526
-
项目类别:
-
资助金额:$34.61万
-
财政年份:2003
-
负责人:THOMAS J SLAGA
-
依托单位:
GR Impairment in Carconogenesis: Tumor Suppressor Role
-
批准号:7452244
-
项目类别:
-
资助金额:$29.91万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
GR IMPAIRMENT IN CARCINOGENESIS--ROLE OF NF KAPPA BETA
-
批准号:6124644
-
项目类别:
-
资助金额:$34.91万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
GR IMPAIRMENT IN CARCINOGENESIS--ROLE OF NF KAPPA BETA
-
批准号:6475818
-
项目类别:
-
资助金额:$36.89万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
GR Impairment in Carconogenesis: Tumor Suppressor Role
-
批准号:6969560
-
项目类别:
-
资助金额:$34.77万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
GR IMPAIRMENT IN CARCINOGENESIS--ROLE OF NF KAPPA BETA
-
批准号:2837808
-
项目类别:
-
资助金额:$33.97万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
GR IMPAIRMENT IN CARCINOGENESIS--ROLE OF NF KAPPA BETA
-
批准号:6329046
-
项目类别:
-
资助金额:$39.21万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
GR Impairment in Carconogenesis: Tumor Suppressor Role
-
批准号:7122528
-
项目类别:
-
资助金额:$30.81万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
GR IMPAIRMENT IN CARCINOGENESIS--ROLE OF NF KAPPA BETA
-
批准号:6759916
-
项目类别:
-
资助金额:$1.5万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
GR IMPAIRMENT IN CARCINOGENESIS--ROLE OF NF KAPPA BETA
-
批准号:2700788
-
项目类别:
-
资助金额:$34.75万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
GR Impairment in Carconogenesis: Tumor Suppressor Role
-
批准号:7642547
-
项目类别:
-
资助金额:$29.91万
-
财政年份:1998
-
负责人:THOMAS J SLAGA
-
依托单位:
IDENTIFICATION OF TUMOR PROMOTION SUSCEPTIBILITY GENES
-
批准号:2749703
-
项目类别:
-
资助金额:$16.29万
-
财政年份:1997
-
负责人:THOMAS J SLAGA
-
依托单位:
CHANGES IN GENES AND GENE EXPRESSION IN CARCINOGENESIS
-
批准号:2098328
-
项目类别:
-
资助金额:$3.11万
-
财政年份:1992
-
负责人:THOMAS J SLAGA
-
依托单位:
海外基金